Holen Sie sich die Stockscreener-App
0.3028
2.23%
0.0066
Handel nachbörslich:
.31
0.0072
+2.38%
Schlusskurs vom Vortag:
$0.2962
Offen:
$0.2922
24-Stunden-Volumen:
1.31M
Relative Volume:
0.62
Marktkapitalisierung:
$57.49M
Einnahmen:
$150.71M
Nettoeinkommen (Verlust:
$-30.94M
KGV:
-1.7136
EPS:
-0.1767
Netto-Cashflow:
$-20.86M
1W Leistung:
-16.12%
1M Leistung:
+4.05%
6M Leistung:
-69.71%
1J Leistung:
-74.55%
1-Tages-Spanne:
$0.2852
$0.3085
1-Wochen-Bereich:
$0.2852
$0.3859
52-Wochen-Spanne:
$0.261
$1.575
Heron Therapeutics Inc Stock (HRTX) Company Profile
Firmenname
Heron Therapeutics Inc
Sektor
Branche
Telefon
(858) 251-4400
Adresse
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Compare HRTX vs VRTX, REGN, MRNA, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
0.3028 | 57.49M | 150.71M | -30.94M | -20.86M | -0.1767 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-08-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2026-06-03 | Herabstufung | Needham | Buy → Hold |
| 2025-06-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-04-23 | Eingeleitet | CapitalOne | Overweight |
| 2024-03-13 | Bestätigt | Needham | Buy |
| 2020-05-27 | Eingeleitet | Guggenheim | Buy |
| 2020-02-20 | Bestätigt | Needham | Buy |
| 2019-01-16 | Bestätigt | Needham | Buy |
| 2018-04-05 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-19 | Bestätigt | Mizuho | Buy |
| 2018-03-01 | Bestätigt | Needham | Buy |
| 2018-01-03 | Eingeleitet | Leerink Partners | Outperform |
| 2017-09-27 | Eingeleitet | Northland Capital | Outperform |
| 2017-02-27 | Eingeleitet | Needham | Buy |
| 2016-10-26 | Eingeleitet | Aegis Capital | Buy |
| 2016-09-06 | Fortgesetzt | Lake Street | Buy |
| 2016-05-03 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-12-10 | Eingeleitet | Lake Street | Buy |
| 2015-09-23 | Bestätigt | Leerink Partners | Outperform |
| 2015-09-02 | Eingeleitet | BofA/Merrill | Buy |
| 2015-08-03 | Bestätigt | Brean Capital | Buy |
| 2015-06-30 | Bestätigt | JMP Securities | Mkt Outperform |
| 2015-06-19 | Bestätigt | Leerink Partners | Outperform |
| 2014-08-07 | Eingeleitet | Noble Financial | Buy |
Alle ansehen
Heron Therapeutics Inc Aktie (HRTX) Neueste Nachrichten
Heron Therapeutics Inc Estimates – BX:AXD2 - TradingView
Form 4 Heron Therapeutics Inc: Craig A. Collard (Director, CEO) For: 19 October - Investing.com Nigeria
Quarterly stock vesting gives Heron Therapeutics (HRTX) development chief 3,874 shares. - Stock Titan
Stock awards convert into 13,797 shares for Heron Therapeutics (HRTX) CEO Craig A. Collard. - Stock Titan
Heron Therapeutics: Acute Care Growth Offset by Oncology Weakness and Financial Uncertainty - Kalkine
Heron Therapeutics, Inc. (HRTX)What Are Investment Firms Thinking About This Stock? - MarketBeat
Heron Therapeutics stock at EUR 0.34 as Nasdaq move reaches 4.4 percent - ad-hoc-news.de
Investors Buy High Volume of Put Options on Heron Therapeutics (NASDAQ:HRTX) - MarketBeat
Heron Therapeutics stock gained 15.86 percent to USD 0.38 - AD HOC NEWS
Heron Therapeutics Q3 2026 Earnings Date and Estimates - MarketBeat
Heron Therapeutics stock faces a guidance reset after Q2 loss - AD HOC NEWS
Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2020 and Highlights Recent Corporate Updates - Lelezard
Heron Therapeutics stock fell 2.33 percent on October 2 - AD HOC NEWS
Form 8K Heron Therapeutics Inc For: 29 September By Investing.com - Investing.com Nigeria
Heron Therapeutics signs multi-product license agreement with Long Grove By Investing.com - Investing.com Nigeria
Heron Therapeutics signs multi-product license agreement with Long Grove - Investing.com
Heron Therapeutics, Inc. (NASDAQ:HRTX) Stock Has Consensus Target Price of $2.00 - MarketBeat
Heron Therapeutics, Inc. (HRTX) Options Chain - finance.yahoo.com
Heron Therapeutics stock awaits its next reported figures - AD HOC NEWS
Heron Therapeutics (AXD2) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Heron Therapeutics Sees Unusually High Options Volume (NASDAQ:HRTX) - MarketBeat
HRTX - Finviz
10,550,750 Shares in Heron Therapeutics, Inc. $HRTX Bought by BlackRock Inc. - marketbeat.com
Heron Therapeutics stock trades at penny level as biotech focuses on pain and oncology pipeline - ad-hoc-news.de
AXD2 Forecast — Price Target — Prediction for 2027 - TradingView
Heron Therapeutics, Inc. (NASDAQ:HRTX) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Heron Therapeutics Stock Short Interest Rises to 31.36% - Quiver Quantitative
Tejara Capital Ltd Buys New Stake in Heron Therapeutics, Inc. $HRTX - MarketBeat
Heron (HRTX) Results Review: EPS Comes in Below Forecast on the Day; Price Reaction: Shares Move 4.13% Down in Latest TradingEarnings Turnaround - vinanet.vn
Heron Therapeutics Earnings Call: Growth Meets New Risks - TipRanks
Heron (HRTX) Watch: Records a 4.65% Increase to $0.31 at the Close; Key Range: the Session Ends Within the Reported Technical Boundaries in the Available RecordIV Contraction - vinanet.vn
H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Hold Rating - Moomoo
Weekly Recap: Guidance withdrawn over CINVANTI patent and HRTX Q2 revenue $37.7M - TradingView
HC Wainwright Has Pessimistic Outlook of HRTX Q3 Earnings - MarketBeat
HERON THERAPEUTICS INC : H.C. WAINWRIGHT CUTS TO NEUTRAL FROM BUY - webull.com
H.C. Wainwright Downgrades Heron Therapeutics(HRTX.US) to Hold Rating - Moomoo
--HC Wainwright Downgrades Heron Therapeutics to Neutral From Buy - Yahoo Finance
Heron Therapeutics (NasdaqCM:HRTX) Stock Forecast & Analyst Predictions - Simply Wall Street
Heron Therapeutics earnings missed by $0.02, revenue fell short of estimates - Investing.com Canada
Heron Therapeutics Inc (HRTX) (Q2 2026) Earnings Call Highlights: Revenue Growth Amid Strategic ... - finance.yahoo.com
Heron Therapeutics Q2 2026 Loss Widens 50.0% Beyond Estimates - AlphaStreet
Heron Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Heron Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat
Heron Therapeutics Withdraws 2026 Guidance as CINVANTI Patent Risk and Strategic Review Cloud Outlook - Yahoo Finance
Earnings call transcript: Heron Therapeutics misses Q2 2026 revenue forecast By Investing.com - Investing.com Canada
Heron Therapeutics Q2 Earnings Call Highlights - MarketBeat
Heron Therapeutics Q2 Earnings Call Highlights - Yahoo Finance
Heron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue Estimates - finance.yahoo.com
development in the article - Minichart
Heron Therapeutics (NASDAQ:HRTX) Issues Earnings Results - MarketBeat
Finanzdaten der Heron Therapeutics Inc-Aktie (HRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.09%
0.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):